Stimulation of Toll-like receptors (TLRs) to activate the innate immune system has been a legitimate therapeutic strategy for some years. Several TLRs, namely 3, 4, 7, 8, and 9, are validated targets for cancer, and pharmaceutical companies are actively developing TLR agonists and vaccine adjuvants.
We have developed two new reporter gene assays, iLite TRL 4 and iLite TLR9, that can be used in assays studying these potential therapeutic agents.